• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Virta Health touts study of treatment preventing progression to Type 2 diabetes

March 2, 2021 By Sean Whooley

Virta HealthVirta Health announced today that a study of its diabetes progression prevention treatment proved more effective than initially expected.

Peer-reviewed research in Nutrients highlighted the fact that only 3% of trial participants progressed to Type 2 diabetes, while over half achieved prediabetes reversal during the first two years, according to a news release.

Additionally, the trial observed 75% of patients retained at the two-year mark. Virta Health said the figures “far exceed” outcomes reported for the National Institutes of Health Diabetes Prevention Program (NIH DPP) and its real-world translation, the National Diabetes Prevention Program (NDPP), which is considered the “gold standard” in the prediabetes treatment space.

Over the two years, while 3% of Virta patients progressed to Type 2 diabetes, other treatments saw less effectiveness. In the NIH DPP trial, 8% progressed to Type 2 diabetes in the lifestyle intervention, compared to 15% of those treated with metformin and 22% in the control group.

Virta observed 52% of patients achieve prediabetes reversal, while the company’s patients also experienced average weight loss of 11.3% at two years, more than doubling the NDPP’s 5% goal for prediabetes. While NDPP’s one-year retention was 13.2%, Virta’s was 80%, dropping to 75% at two years.

“The overwhelming number of patients who either achieve normal blood sugar or avoid progression to type 2 diabetes further demonstrates the effectiveness of Virta’s reversal treatment on a variety of metabolic conditions,” Virta Health CMO Dr. Robert Ratner said in the release. “Nutrition modifications can be hard to sustain, but the remarkable adherence and retention demonstrate both the acceptability and durability of the Virta approach in both prevention and treatment of diabetes.”

Virta Health launched in 2017 with a goal of reversing Type 2 diabetes using its technology platform to enable personalized remote care. The company provides physician supervision, health coaches, an app and biomarker tracking tools, as well as a personalized nutrition plan for its patients in the hopes of reversing Type 2 diabetes. According to the company, in clinical studies, 94% of its patients reduce or eliminate insulin use.

Filed Under: Clinical Trials, Diabetes, Featured Tagged With: Diabetes, Virta Health

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS